Fig 4.

Lamstatin and CP17 reduce cell viability and inhibit cord formation of proliferating human umbilical vein endothelial cells (HUVECs). Subconfluent HUVECs were treated for 72 hrs with (A) lamstatin and manually counted using trypan blue exclusion (n = 6 experimental repeats) (data expressed as average number of cells/ml). Subconfluent HUVECs were treated for 72 hrs with (B) lamstatin or (C) CP17 and cell viability, measured with MTT, was expressed as percentage of vehicle control (% VC) (n = 6 and n = 6 experimental repeats). All data are expressed as mean ± SE of the mean (SEM) and compared using one-way repeated measures anova (Bonferroni correction for multiple comparisons) of various concentrations versus no treatment *P < 0.05. HUVECs were seeded on geltrex-coated plates for 2 hrs before being treated with lamstatin (10 μg/ml), vehicle or CP17 (10 μg/ml) for up to 18 hrs. (D) Cord formation in the presence of lamstatin (n = 4 experimental repeats) or (E) CP17 (n = 4 experimental repeats). Data are expressed as mean ± SE of the mean (SEM) of cords per 1000 square pixel (px²) and compared using paired student's t-test, *P < 0.05.